Key Takeaways
Insilico Medicine reported in Nature Biotechnology on September 7 that its AI-designed drug rentosertib appeared to reverse biological age in a Phase IIa trial, as measured by six independent proteomic aging clocks.
Rentosertib is the first drug candidate with both an AI-discovered target, the protein TNIK, and a molecule designed by generative AI.
The strongest signal showed roughly three to four years of biological age reversal, with up to six years on one clock, though the authors call the result exploratory.
On September 7, Insilico Medicine published a study in Nature Biotechnology showing that its experimental drug rentosertib appeared to make patients biologically younger, and six separately built aging clocks all agreed.
Rentosertib did not start as an anti-aging drug. It was built to treat idiopathic pulmonary fibrosis, a scarring lung disease with a median survival of three to four years. Insilico used its AI platform to pick the target, a protein called TNIK, and its generative chemistry system to design the molecule, which makes it the first drug candidate with both an AI-found target and an AI-designed structure.
For the new analysis, researchers went back to blood samples from a 42-patient trial and ran the proteins through six aging clocks built independently by teams at Harvard, Oxford, Peking University and Insilico. All six pointed the same way. Patients on the drug looked younger, with about three to four years of reversal at week four and up to six years on one clock.
The agreement is the part worth sitting with. The six models share neither their inputs nor their training data, so six methods landing on the same result is hard to wave off as noise.
"What convinces me is not the size of the effect but the agreement"
Michael Levitt, 2013 Nobel laureate in Chemistry
The authors are careful about what this is not. The trial cannot yet separate a real slowing of aging from simply treating a sick lung, and the clean test is a study in healthy people. Rentosertib has already moved into a Phase III trial for the lung disease.
It is the kind of result worth watching, part of the same shift that has regulators writing the rules for AI inside medical devices and frontier labs being judged on what their models can actually deliver. The pattern here is hard to ignore, AI is starting to design the medicine, not just read the chart.
People Also Ask
What is rentosertib?
Rentosertib is an experimental drug from Insilico Medicine that inhibits a protein called TNIK. It was designed with generative AI and is being tested for idiopathic pulmonary fibrosis, now in a Phase III trial.
What are proteomic aging clocks?
They are models that estimate a person's biological age from the mix of proteins in their blood. This study used six of them, built by different research groups, to check rentosertib's effect.
Did rentosertib actually reverse aging?
Across six clocks, treated patients showed a lower predicted biological age, up to six years on one model. The authors call it a promising but exploratory signal that needs a trial in healthy volunteers to confirm.
Why does an AI-designed drug matter?
Rentosertib is the first candidate with both an AI-discovered target and an AI-designed molecule, which suggests AI can shorten the slow, costly path from biology to a working drug.